Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-19719

Rizzo, M; Spinas, G A; Rini, G B; Berneis, K (2010). Is diabetes the cost to pay for a greater cardiovascular prevention? International Journal of Cardiology, 144(2):309-310.

[img] PDF - Registered users only
1MB

Abstract

The recent JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial is another study providing evidence about the effectiveness of statin therapy in reducing cardiovascular risk. Yet, in this study significantly higher glycated hemoglobin levels and incidence rates of diabetes were observed in persons treated with rosuvastatin than the placebo group. It should be noted that adverse effects on glucose metabolism have already been reported, albeit rarely, in previous trials with statins. Although the exact mechanisms involved are unknown, it seems that statins may deteriorate glycemic control by decreasing different metabolites, including isoprenoid and ubiquinone, normally produced during the process of cholesterol synthesis. We therefore suggest that, if statins are prescribed, patients should be monitored closely for blood glucose control even though the higher incidence of diabetes by statin therapy may represent a rare finding.

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Endocrinology and Diabetology
DDC:610 Medicine & health
Language:English
Date:2010
Deposited On:01 Dec 2009 15:43
Last Modified:27 Nov 2013 19:47
Publisher:Elsevier
ISSN:0167-5273
Publisher DOI:10.1016/j.ijcard.2009.03.001
PubMed ID:19297038
Citations:Web of Science®. Times Cited: 3
Google Scholar™
Scopus®. Citation Count: 6

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page